Table 1 Characteristics of all B-ALL patients in CR1.
Characteristics | Chemotherapy based(n = 61) | TBI-based(n = 117) | P |
|---|---|---|---|
Gender | 0.280 | ||
Male | 38(62.3%) | 63(53.8%) | |
Female | 23(37.7%) | 54(46.2%) | |
Age (years) | 0.566 | ||
≤ 35 | 33 (54.1%) | 58(59.6%) | |
≥ 35 | 28(45.9%) | 59(50.4%) | |
WBC count at diagnosis (109/L) | 18.6(1.6–263.31) | 14.65(0.1–424.83) | 0.429 |
Central nervous system leukemia before transplantation | 0.168 | ||
No | 60(98.4%) | 108(92.3%) | |
Yes | 1(1.6%) | 9(7.7%) | |
ALL type | 0.158 | ||
Ph− | 25(41.0%) | 61(52.1%) | |
Ph+ | 36(59.0%) | 56(47.9%) | |
Risk group assignment | 0.234 | ||
standard risk | 6(9.8%) | 6(5.1%) | |
high risk | 55(90.2%) | 111(94.9%) | |
MRD status after 3 cycle chemotherapy | 0.895 | ||
Negative | 34(55.7%) | 64(54.7%) | |
Positive | 27(44.3%) | 53(45.3%) | |
Donor | 0.068 | ||
Allo | 46(75.4%) | 101(86.3%) | |
Autologous | 15(24.6%) | 16(13.7%) | |
Duration from diagnosis to transplantation, range (months) | 9(6–16) | 8(2–14) | 0.004 |
Chemotherapy cycles before HSCT | 5(3–8) | 5(3–11) | 0.287 |
Lumbar puncture before HSCT | 6(3–11) | 6(0–13) | 0.307 |
Stem cell source | 0.039 | ||
PBSCs | 58(95.1%) | 116(99.1%) | |
BM | 0 (0) | 1(0.9%) | |
PBSCs + BM | 3(4.9%) | 0 | |
MNC count infused (108/kg) | 10.0(2.08–28.48) | 11.59(1.63–39.52) | 0.037 |
CD34+ cell count infused (106/kg) | 2.53(1.07–12.84) | 3.07(1.38–11.38) | 0.040 |
Maintenance after transplantation | 0.151 | ||
No | 36(59.0%) | 82(70.1%) | |
TKI ± VP/MM/Venetoclax | 17(27.9%) | 24(20.5%) | |
VP/MM/Venetoclax | 7 (11.5%) | 11(9.4%) | |
DLI | 1 (1.6%) | 0 |
